HaemoCer™ PLUS Absorbable Polysaccharide Haemostat (APH) is a proprietary patent pending technology created via BioCers Polysacchidaride Ultra-hydrophilic Resorbable Engineering (PURE) process.
HaemoCer™ PLUS APH incorporates a sophisticated, plant-based polymer crosslinking that creates ultra-hydrophilic, biocompatible particles. Upon contact with blood HaemoCer™ PLUS enhances the natural clotting cascade by rapidly dehydrating the blood and accelerating the concentration of platelets, red blood cells and coagulation proteins at the bleeding site. HaemoCer™ PLUS also on blood interaction rapidly produces a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.
HaemoCer™ PLUS contains no animal or human components and is rapidly resorbed and degraded by histaminases, including amylase and glucoamylase. HaemoCer™ PLUS is indicated for use in surgical procedures or injuries as an adjunct haemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical. BioCers’ proprietary patent pending technology HaemoCer™ PLUS is CE marked and manufactured in Germany. HaemoCer™ PLUS is available in most international markets where CE mark is accepted.
HaemoCer™ PLUS APH exhibits all the key features required by surgical professionals, namely: